ABL1 and uveal melanoma: For instance, imatinib, which targets BCR-ABL, c-Abl, PDGFR and c-Kit, was found not be effective in uveal melanoma despite high expression of KIT, an unexpected finding that was interpreted to be related to the lack of ERK phosphorylation in these tumors (6).